A recent study conducted by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) suggests promising new therapies for patients with squamous and adenocarcinoma non-small cell lung cancers (NSCLC) that do not respond to current immunotherapy treatments. The findings, published in the journal Science Translational Medicine, indicate a potential pathway for enhancing clinical outcomes for these challenging cancer types.
Targeting Tumor Survival Pathways
The study highlights the effectiveness of therapies that simultaneously target lysosomes—cellular particles essential for maintaining stability and nutrient availability—and a protein known as SREBP-1, which increases glucose uptake and contributes to tumor resistance against existing treatments. Deliang Guo, Ph.D., who serves as the founding director of the Center for Cancer Metabolism at OSUCCC–James, acted as the senior author of the study. His colleague, Yaogang Zhong, Ph.D., a senior researcher in Guo’s lab, took on the role of first author.
Guo stated, “These findings reveal a previously unrecognized mechanism by which tumors withstand lysosomal inhibition, providing a strong rationale for combination strategies targeting lysosomal function alongside glucose and lipid metabolism to more effectively treat NSCLC.” He also noted that this approach could extend to other cancers characterized by high metabolic demands, thereby broadening the strategy for improving therapeutic outcomes.
Challenges of Lysosomal Inhibition
Previous attempts to inhibit lysosomes in various cancer types using chloroquine (CQ) in conjunction with radiation, chemotherapy, and targeted agents have often resulted in only modest responses during clinical trials. This preclinical study utilized cell lines and animal models to explore how tumor cells evade lysosomal suppression. The researchers sought to identify strategies that could counteract this resistance.
The study found that inhibiting glucose transport can overcome tumor resistance to CQ treatment by inducing mitochondrial damage, oxidative stress, and ultimately leading to tumor cell death. Guo remarked, “Our study is the first to reveal a previously unrecognized mode in which glucose and lipid metabolism are coupled to form a positive regulatory feedback loop.” This finding enhances the understanding of complex metabolic networks in biological systems and unveils the adaptive capabilities of tumors to evade targeted metabolic therapies.
Zhong emphasized the significance of the research, saying, “This study provides clear mechanistic guidance and a feasible drug-combination strategy to markedly enhance the antitumor efficacy of lysosomal inhibitors.” He added that targeting both lysosomal function and the glucose-lipid metabolic feedback loop presents an efficient antitumor strategy, particularly for patients with lung squamous cell carcinoma and certain subsets of lung adenocarcinoma who lack actionable driver mutations.
Notably, both CQ and simvastatin are clinically approved and repurposed drugs. Furthermore, the fatty acid synthesis inhibitor TVB-2640 has already progressed to phase II/III clinical trials, accelerating the potential for clinical translation and validation of this combination therapy approach.
The insights from this study could pave the way for new treatment protocols that significantly improve the prognosis for patients grappling with some of the most challenging forms of lung cancer. As research continues, the hope is that these findings will translate into effective therapies that enhance patient outcomes and provide new avenues for those with limited treatment options.
